2013
DOI: 10.1073/pnas.1211118110
|View full text |Cite
|
Sign up to set email alerts
|

Chemical polysialylation of human recombinant butyrylcholinesterase delivers a long-acting bioscavenger for nerve agents in vivo

Abstract: The creation of effective bioscavengers as a pretreatment for exposure to nerve agents is a challenging medical objective. We report a recombinant method using chemical polysialylation to generate bioscavengers stable in the bloodstream. Development of a CHO-based expression system using genes encoding human butyrylcholinesterase and a proline-rich peptide under elongation factor promoter control resulted in self-assembling, active enzyme multimers. Polysialylation gives bioscavengers with enhanced pharmacokin… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
60
0

Year Published

2013
2013
2021
2021

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 73 publications
(60 citation statements)
references
References 42 publications
(47 reference statements)
0
60
0
Order By: Relevance
“…These activities of protein-independent polySia have great potential for the development of novel carbohydrate-dependent therapeutics. Likewise, improving the efficacy of therapeutic proteins (e.g., erythropoietin and buturylcholinesterase) using polySia was demonstrated by chemical conjugation and in vitro approaches (7,8,44). Clinical trials of polySia-conjugated recombinant proteins are ongoing, indicating the pharmaceutical relevance of polySia (reviewed in ref.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…These activities of protein-independent polySia have great potential for the development of novel carbohydrate-dependent therapeutics. Likewise, improving the efficacy of therapeutic proteins (e.g., erythropoietin and buturylcholinesterase) using polySia was demonstrated by chemical conjugation and in vitro approaches (7,8,44). Clinical trials of polySia-conjugated recombinant proteins are ongoing, indicating the pharmaceutical relevance of polySia (reviewed in ref.…”
Section: Discussionmentioning
confidence: 99%
“…1, 2, 5, and 6). Notably, chemical or in vitro polySia engineering has made a substantial impact on pharmacokinetic properties of recombinant glycoprotein therapeutics (7,8). These examples demonstrate a manifold functional impact of polySia and highlight the great potential for the development of novel polySia-dependent therapeutics.…”
mentioning
confidence: 99%
“…A combination of both pathways also was observed for cl.15. The selected BChE mutants were of high interest because they revealed a previously unreported target (the BChE acylbinding loop) for the creation of catalytic bioscavengers based on human BChE, which are used extensively for protection against nerve agent poisoning and postexposure treatment (12,13).…”
Section: -Stenotrophomonasmentioning
confidence: 99%
“…4 For instance, chemical conjugation with suitable glycans has been exploited for the production of therapeutic enzymes with improved activity and reduced in vivo metabolism. 5 Neoglycoproteins, which contain unnatural linkages between protein and saccharides, can also provide carbohydrate antigens and immunogens from which immunodiagnostic and therapeutic reagents can be derived. 4 For example, conjugation of antigenic proteins from Mycobacterium tuberculosis with arabino-mannane polysaccharides has been proposed for developing highly immunogenic glycoconjugate vaccines against tuberculosis.…”
Section: Introductionmentioning
confidence: 99%